The global gabapentin market size reached US$ 2.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.9 Billion by 2028, exhibiting a growth rate (CAGR) of 5.7% during 2023-2028. The rising neuropathic conditions, increasing drug versatility in treating off-label drugs, ongoing opioid crises, the implementation of favorable government policies, rapid technological advancements and ongoing research and development (R&D) efforts are some of the major factors propelling the market.
|Market Size in 2022
||US$ 2.1 Billion
|Market Forecast in 2028
||US$ 2.9 Billion
|Market Growth Rate (2023-2028)
Gabapentin is a medication primarily used to treat seizures and neuropathic pain. It is a gamma-aminobutyric acid (GABA) analog that does not bind directly to GABA receptors. Gabapentin is available in multiple forms, such as capsules, tablets, and oral solutions, and also comes in an extended-release version known as Gabapentin ER. It includes the active ingredient gabapentin and inert ingredients like cornstarch and talc, which vary depending on the manufacturer. It helps in treating epileptic seizures and neuropathic pain and is also utilized off-label for conditions like restless leg syndrome and anxiety disorders. Additionally, it is generally well-tolerated and offers a lower risk profile for dependency compared to opioids, making it a preferable option for long-term management of certain chronic pain conditions. Gabapentin is a versatile medication with applications in neurology and psychiatry, presenting a valuable opportunity for medical practitioners.
The rising conditions like diabetes and shingles that cause neuropathic pain and the growing geriatric population are major factors propelling the market growth. Besides this, the widespread utilization of gabapentin in treating various off-label conditions like anxiety disorders and restless leg syndrome is providing a thrust to the market growth. Moreover, the ongoing opioid crisis leading to a search for alternative pain management solutions, positioning gabapentin as a lower-risk option for chronic pain treatment is positively impacting the market growth. In addition to this, the implementation of favorable government policies leading to relaxed prescribing rules and generic availability, making gabapentin accessible and cost-effective, is supporting the market growth. Apart from this, rapid technological advancements leading to improved formulation techniques, such as extended-release options making the medication more user-friendly and effective, are providing an impetus to the market growth. Along with this, the ongoing research to discover new therapeutic applications for gabapentin is also propelling the market growth. In confluence with this, the increasing partnerships between pharmaceutical companies for the distribution and marketing of gabapentin are providing remunerative growth opportunities for the market.
Gabapentin Market Trends/Drivers:
Increasing prevalence of neuropathic pain
The growing incidence of neuropathic pain across the globe is one of the most significant factors driving the market growth. Neuropathic pain is a complex, chronic pain state that typically accompanies conditions, such as diabetes, shingles, and certain types of injuries. Moreover, the growing occurrence of shingles that can lead to post-herpetic neuralgia, a form of neuropathic pain, is supporting the market growth. Additionally, the increasing geriatric population leading to a growing rate of chronic conditions, necessitating the requirement for effective treatment options, is providing a considerable boost to the market growth. The ability of gabapentin to offer relief with a relatively low risk of dependency makes it a preferred choice among clinicians and patients, thereby substantially influencing its market growth. In addition to this, the development of improved diagnostic techniques for identifying neuropathic pain, such as advanced imaging technologies and better clinical awareness, is also providing a considerable boost to the market growth.
Growing product versatility
The widespread utilization of gabapentin in treating off-label conditions, such as anxiety disorders is contributing to the market growth. Physicians often prescribe Gabapentin for conditions like restless leg syndrome, migraine prophylaxis, and various anxiety disorders. Besides this, several smaller-scale studies and clinical reports have cited its efficacy in reducing symptoms of anxiety, is supporting the market growth. Furthermore, the increasing drug utilization in substance abuse treatment programs, such as alcohol withdrawal management and as an adjunct in the treatment of opioid addiction is creating a positive outlook for the market growth. The empirical evidence supporting its efficacy in these applications remains in developmental stages, but the initial findings are promising, thus encouraging further research and off-label prescribing.
Rising product utilization in opioid crises
The escalating opioid crisis is creating a positive outlook for the market growth. In addition to this, the increasing utilization of gabapentin as an alternative to opioids since it is a safer option that offers an effective treatment for chronic and neuropathic pain without the opioid-associated risk of dependency is providing a thrust to the market growth. Moreover, the growing support by regulatory bodies and healthcare organizations for the utilization of gabapentin as a frontline treatment for certain types of pain is positively impacting the market growth. Besides this, the rising role of gabapentin as an alternative to opioids, particularly crucial in chronic care settings and among patients who require long-term pain management, is favoring the market growth. Furthermore, the rising shift towards safer alternatives away from opioids, supported by public awareness campaigns and educational efforts by governmental and non-governmental organizations, is providing an impetus to the market growth.
Gabapentin Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global gabapentin market report, along with forecasts at the global, regional, and country levels for 2023-2028. Our report has categorized the market based on dosage form, type, application, and distribution channel.
Breakup by Dosage Form:
- Oral Solutions
Capsule dominate the market
The report has provided a detailed breakup and analysis of the market based on the dosage form. This includes tablet, capsule, and oral solutions. According to the report, capsule represented the largest segment.
The increasing utilization of capsules, as they are generally easier to swallow compared to tablets, especially advantageous for older patients or those with swallowing difficulties, is one of the major factors supporting the market growth. Additionally, the capsule form of gabapentin is designed for quick dissolution and absorption in the gastrointestinal tract. It allows for rapid onset of action, making it particularly useful for conditions requiring immediate relief, such as acute neuropathic pain episodes or seizures. Besides this, capsules often come in various strengths, allowing customized dosing tailored to individual patient's needs, helping healthcare providers optimize treatment plans, and improving patient outcomes. In addition, the increasing preference for capsules over other dosage forms like tablets or liquids due to their ease of use and lack of taste contributes to better adherence to medication regimens, favoring the market growth. Furthermore, capsules usually have a longer shelf life and are less sensitive to environmental factors like humidity compared to other forms like oral solutions, which makes them more convenient for suppliers and end-users.
Breakup by Type:
Generic dominate the market
The report has provided a detailed breakup and analysis of the market based on the type. This includes generic and branded. According to the report, generic represented the largest segment.
Generic gabapentin is considerably cost-effective than its branded counterparts, making it more accessible to a wider patient population, which in turn, is creating a positive outlook for the market growth. Moreover, the generic versions of the drug are required to demonstrate bioequivalence to the branded drug, offering the same active ingredient, strength, dosage form, and route of administration, ensuring their effectiveness favoring the market growth. Besides this, the increasing availability of generic drugs, as multiple manufacturers produce them, is providing a thrust to the market growth. In addition to this, many healthcare insurance plans encourage or mandate the use of generic medications as first-line treatment options in their formularies, incentivizing healthcare providers and consumers to opt for generic gabapentin. Apart from this, the increasing focus on healthcare affordability, encouraging consumers to become more knowledgeable about generic drugs' efficacy and cost benefits is positively impacting the market growth.
Breakup by Application:
- Neuropathic Pain
- Restless Legs Syndrome
Epilepsy hold the largest share in the market
A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes epilepsy, neuropathic pain, restless legs syndrome, and others. According to the report, epilepsy accounted for the largest market share.
The increasing efficacy of gabapentin in managing seizures, making it a trusted option among healthcare providers, is one of the major factors propelling the market growth. In line with this, gabapentin is often used as an adjunctive therapy along with other antiepileptic drugs, allowing clinicians to better tailor treatment regimens for individual patients. Besides this, the growing utilization of gabapentin, which has a relatively mild side-effect profile that makes it a preferred option for long-term treatment plans, contributes to higher patient adherence and is supporting the market growth. Moreover, gabapentin has been studied and found effective in pediatric populations to treat partial seizures, further enlarging its market share within the epilepsy segment. In addition to this, gabapentin is effective in managing various types of seizures, including partial seizures and generalized seizures, increasing its applicability and making it a go-to option for multiple epilepsy subtypes. Apart from this, the widespread availability of generic versions makes gabapentin a cost-effective solution, facilitating its general use in treating epilepsy, even in lower-income countries or healthcare systems.
Breakup by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Hospital pharmacy dominate the market
The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacy, retail pharmacy, and online pharmacy. According to the report, hospital pharmacy represented the largest segment.
The increasing utilization of gabapentin in hospital pharmacies, especially for conditions like epilepsy or severe neuropathic pain, as doctors prefer to prescribe the medication where it can be closely monitored initially, is supporting the market growth. Besides this, hospital pharmacies are often highly regulated and subject to stringent quality control measures, ensuring that the medication dispensed is stored correctly and is of the highest quality. Moreover, the immediate availability of drugs for acute conditions that require prompt medication, making hospital pharmacies a preferred distribution channel in urgent situations, is providing an impetus to the market growth. In addition to this, hospital pharmacies are part of an integrated care system, where prescriptions can be filled immediately following a consultation or treatment, offering convenience to patients and ensuring medication adherence. Furthermore, the increasing availability of gabapentin drugs in the hospital pharmacies required in emergencies, especially involving acute seizures or severe pain episodes, as they are designed to provide this rapid access, is favoring the market growth.
Breakup by Region:
- North America
- United Kingdom
- Asia Pacific
- South Korea
- Latin America
- Middle East and Africa
North America exhibits a clear dominance, accounting for the largest gabapentin market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America is leading the gabapentin market as the region has a highly developed healthcare system that accommodates extensive medical research and drug development programs, naturally positioning it as a leading pharmaceutical market, including gabapentin. Additionally, the increasing availability of health insurance and medical care programs in the region helps to make medications like gabapentin more accessible to the population, increasing the usage rate thereby boosting the market growth. Moreover, the rising consumer awareness about healthcare and medication options due to growing emphasis on health, is creating a positive outlook for the market growth. Apart from this, the competitive generic pharmaceutical sector in the region, promoting the use of cost-effective medications, is propelling the market growth. Furthermore, North America invests heavily in pharmaceutical research and development (R&D), allowing for constant innovation and new applications for drugs like gabapentin, broadening its market scope.
The leading companies in the gabapentin market are investing heavily in research and development (R&D) to discover new applications for gabapentin and improve its formulation. It helps in extending the lifecycle of the product and tapping into new market segments. Besides this, companies are entering emerging markets where the healthcare infrastructure is developing, offering growth potential due to rising healthcare needs and increasing awareness of conditions treated by gabapentin. Moreover, some firms are acquiring or partnering with other companies to expand their product portfolios or to accelerate the R&D process, aiming to combine expertise and resources. Additionally, many pharmaceutical companies are producing generic versions of gabapentin, allowing them to quickly capture a share of the market due to the lower cost of generic medications. In line with this, the key companies are continually working on improving the quality of gabapentin by adopting the latest manufacturing techniques, ensuring compliance with regulatory guidelines, and undertaking rigorous quality checks. Furthermore, some companies use direct-to-consumer (DTC) advertising to raise awareness about gabapentin’s applications and benefits, particularly in regions where this type of advertising is permitted.
The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
- Alkem Laboratories Limited
- Amneal Pharmaceuticals LLC
- Apotex Inc.
- Aurobindo Pharma Limited
- Azurity Pharmaceuticals, Inc.
- Cipla Inc.
- Glenmark Pharmaceuticals Limited
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Zydus Pharmaceuticals (USA) Inc. (Zydus LifeScience)
Gabapentin Market Report Scope:
|Base Year of the Analysis
| Historical Period
|Scope of the Report
||Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
- Dosage Form
- Distribution Channel
|Dosage Forms Covered
||Tablet, Capsule, Oral Solutions
||Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Others
|Distribution Channels Covered
||Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
||Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Alkem Laboratories Limited, Amneal Pharmaceuticals LLC, Apotex Inc., Aurobindo Pharma Limited, Azurity Pharmaceuticals, Inc., Cipla Inc., Glenmark Pharmaceuticals Limited, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Zydus Pharmaceuticals (USA) Inc. (Zydus LifeScience), etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the global gabapentin market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global gabapentin market?
- What is the impact of each driver, restraint, and opportunity on the global gabapentin market?
- What are the key regional markets?
- Which countries represent the most attractive gabapentin market?
- What is the breakup of the market based on the dosage form?
- Which is the most attractive dosage form in the gabapentin market?
- What is the breakup of the market based on the type?
- Which is the most attractive type in the gabapentin market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the gabapentin market?
- What is the breakup of the market based on the distribution channel?
- Which is the most attractive distribution channel in the gabapentin market?
- What is the competitive structure of the global gabapentin market?
- Who are the key players/companies in the global gabapentin market?
Key Benefits for Stakeholders:
- IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the gabapentin market from 2017-2028.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the global gabapentin market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the gabapentin industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.